Background {#Sec1}
==========

Infective endocarditis (IE) is an infection of the endocardium and heart valves or of a prosthetic valve implant \[[@CR1]\]. Great strides have been made in the treatment of IE since Osler's observation of the disease in the nineteenth century. However, IE continues to be a significant cause of morbidity and mortality \[[@CR2], [@CR3]\]. The epidemiology of IE has changed, especially in high-income countries that have observed a significant reduction in IE related to rheumatic disease; while degenerative valvulopathies, prosthetic valve IE (PVE), IE related to cardiovascular implantable electronic devices (CIED) and IE in persons who inject drugs (PWID) have all increased \[[@CR4], [@CR5]\]. Presentation with different complications including heart failure, embolic events, abscess formation, conductive disorders, and large vegetation size has been associated with increased in-hospital mortality in patients with IE \[[@CR6]--[@CR8]\].

Troponins are cardiac specific proteins released in case of cardiomyocyte injury. Elevated troponin levels can be a poor predictor of patient's outcome in many disease states, including coronary artery disease, pulmonary embolism, heart failure, and other cardiac and non-cardiac conditions \[[@CR9]\]. There have been some reports with small sample sizes on using troponin as a clinical predictor of mortality in patients with IE \[[@CR9], [@CR10]\].

The objective of this study was to describe variables that would predict an increased likelihood of inpatient mortality in patients presenting with IE, and to evaluate the role and usefulness of serum troponin levels measurements as a marker of increased mortality.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

This case-control study included adult patients (aged ≥18 years) with IE admitted to a tertiary care hospital in east Tennessee between December 2012 and July 2017. Data was gathered through retrospective chart review of the electronic medical record. Only the first patient admission for IE was included. The search term "endocarditis" was used on the discharge diagnoses to narrow down the search results. This yielded "endocarditis acute, sub bacterial" and "endocarditis NOS" with ICD 9 codes 421.0 and 424.9, respectively. Patients who met inclusion criteria were confirmed to have definitive IE by the modified Duke Criteria \[[@CR11]\].

Data collected included the patients' demographic and baseline clinical information, microbiological data according to Clinical and Laboratory Standards Institute standards, injection drug use status, hepatitis C status, human immunodeficiency virus (HIV) status, acute renal failure with serum creatinine level of more 2 mg/dl on presentation, requirement of hemodialysis, diabetes mellitus, atrial fibrillation, heart failure, elevated serum troponins levels within 2 days of admission, and severe sepsis/shock during admission. The study was approved by University of Tennessee Graduate School of Medicine institutional review board.

Outcome measures and key definitions {#Sec4}
------------------------------------

Cases were defined as patients with definitive IE who died in-hospital; controls were patients who did not die in hospital. Troponin I values were considered elevated if they were ≥ than 0.78 ng/ml as per manufacturers recommendation (Siemens) for critical high, first positive result for the patients were included.

Statistical analyses {#Sec5}
--------------------

This study was designed to determine risk factors for in-hospital mortality for patients with IE. The exposure of interest was elevated troponin. Descriptive and bivariate analyses were utilized to describe differences in the patient population. Categorical and continuous variables were compared using the Chi-Square, Fisher's Exact, or Mann-Whitney U-tests. Classification and regression tree (CART) analyses were performed to identify dichotomous breakpoints in continuous variables associated with mortality. Variables associated with in-hospital mortality from bivariate analyses (*P* \< 0.2) or deemed clinically relevant a priori were considered for inclusion into a multivariable logistic regression model. Variables were manually entered into the model using a backwards, step-wise approach in order to determine variables independently associated with developing in-hospital mortality while controlling for potential confounders. Other variables were excluded from the model because of unmet clinical or statistical criteria, to preserve the n:k ratio, or to prevent collinearity. The final model was evaluated for goodness-of-fit using the Hosmer-Lemeshow test. All statistics were performed with IBM SPSS Statistics for MacIntosh v.25 (IBM Corp., Armonk, NY).

Results {#Sec6}
=======

Two-hundred and eighty-three patients with IE were included; baseline patient characteristics are listed in Table [1](#Tab1){ref-type="table"}. The median (IQR) age was 41 (30--57) years, and 153 (54%) patients were men. The median (IQR) length of hospital stay was 14 (9--24) days, and 24 (9%) patients left against medical advice. One-hundred sixty-four (58) patients injected illicit drugs, and 110 patients (39%) were positive for hepatitis C virus. The most frequent IE type was: 167 (59%) right-sided, 86 (30%) left-sided, 24 (9%) both left and right-sided, and 10 (4%) device related. Two-hundred twelve (75%) patients had a troponin level obtained, and 57 (27) had an elevated troponin value. Table [2](#Tab2){ref-type="table"} includes patient characteristics of patients with a troponin value on admission. Table 1Baseline characteristics of infective endocarditis patients who survived and diedCharacteristic *n* (%) or median (IQR)Total Population *n* = 283Died in Hospital *n* = 36Alive *n* = 247*P*-valuePatient Characteristics Age, years41 (30--57)46 (33--63)40 (29--56)0.14 Sex, male153 (54%)24 (67%)129 (52%)0.10Comorbidities HIV/AIDS4 (1%)04 (62%)1.0 Injection drug use164 (58%)24 (67%)140 (57%)0.26 Hepatitis C virus110 (39%)7 (19%)103 (42%)0.01 Diabetes mellitus40 (14%)5 (14%)35 (14%)0.96 Heart failure64 (23%)8 (22%)56 (23%)1.0 Atrial fibrillation31 (110%)7 (19%)24 (10%)0.09 Hemodialysis15 (5%)015 (6%)0.23 Acute renal failure/hemodialysis99 (35%)27 (75%)72 (29%)\< 0.001 Septic shock93 (33%)28 (78%)65 (26%)\< 0.001 Troponin obtained212 (75%)33 (92%)179 (73%)0.01Infection Characteristics and Outcomes Septic Emboli151 (54%)27 (75%)124 (50%)0.005 Left-sided IE86 (30%)18 (50%)68 (28%)0.01 IE Valve Surgery44 (16%)044 (18%)0.01 MRSA IE91 (32%)16 (44%)75 (30%)0.09 LAMA24 (9%)024 (10%)0.05 Table 2Characteristics of infective endocarditis patients with troponin levelsCharacteristic *n* (%) or median (IQR)Elevated Troponin Level *n* = 57Normal Troponin level *n* = 155*P*-valuePatient Characteristics Age, years44 (30--59)40 (30--55)0.5 Sex, male27 (47%)74 (48%)1.0Comorbidities Injection Drug Use34 (60%)90 (58%)0.84 Hepatitis C virus14 (25%)74 (48%)\< 0.001 Diabetes mellitus7 (12%)22 (14%)0.72 Heart failure17 (30%)17 (30%)0.34 Atrial fibrillation5 (9%)21 (14%)0.35 Acute Renal failure/Hemodialysis30 (53%)50 (32%)0.007 Sepsis/septic shock40 (70%)43 (28%)\< 0.001Infection Characteristics and Outcomes Septic emboli49 (86%)69 (45%)\< 0.001 Left-sided IE31 (54%)37 (24%)\< 0.001 Valve surgery16 (28%)17 (11%)0.002 Died in-hospital19 (33%)14 (9%)\< 0.001

Two-hundred eighty-one organisms were isolated from 249 (88%) patients; 34 (12%) patients had culture negative IE. The most commonly isolated aggregate organisms were 91 (32%) methicillin-resistant *Staphylococcus aureus*, 50 (18%) methicillin-sensitive *S. aureus*, 38 (14%) *Enterococcus* spp., 26 (9%) *Streptococcus* spp., 17 (6%) *Pseudomonas aeruginosa*, 5 (2%) other Gram-negatives (*Klebsiella* spp., *Enterobacter* spp., and *Serratia* spp.), and 19 (7%) other organisms.

Thirty-six (13%) patients died in-hospital due to any cause. The results of bivariate analyses and clinical rationale dictated the variables selected for inclusion into a multivariable regression model (Table [3](#Tab3){ref-type="table"}). Variables associated with in-hospital mortality were elevated troponin (adjusted odds ratio \[adjOR\], 7.3; 95%CI, 3.3--15.9), and MRSA IE (adjOR 2.6; 95%CI, 1.2--5.8). Variables identified to significantly covary with elevated troponin values were: acute renal dysfunction, left-sided endocarditis, severe sepsis/shock, and septic emboli. Hepatitis C virus was excluded as a variable of interest due to the lack of causal inference related to this association. Significant collinearity (*P* \< 0.001) was identified between elevated troponin levels and atrial fibrillation, severe sepsis/shock, acute renal failure, left-sided IE, and septic emboli, which ultimately precluded inclusion of these variables into the final parsimonious model. Given that no patients who received IE valve surgery died, this variable was unable to converge in the final model and was excluded. Table 3Variables associated with all-cause, in-hospital mortality^a^CharacteristicUnadjusted OR 95%CI*P*-valueAdjusted OR 95%CI*P*-valueElevated troponin6.1 (2.9--12.9)\< 0.0017.3 (3.3--15.9)\< 0.001Severe Sepsis/Shock9.8 (4.3--22.3)\< 0.001Not Tested--Acute renal failure7.2 (3.3--16.3)\< 0.001Not Tested--Septic emboli3.0 (1.3--6.6)0.005Not Tested--Left-sided IE2.6 (1.3--5.4)0.006Not Tested--Atrial Fibrillation2.2 (0.89--5.7)0.092.7 (0.97--7.8)0.06Age greater than 40 years1.9 (0.95--4.1)0.072.0 (0.9--4.6)0.09MRSA IE1.8 (0.9--3.7)0.122.6 (1.2--5.8)0.02Heart failure0.97 (0.42--2.3)0.95Not Tested--Valve surgery0.85 (0.81--0.9)0.01Not Tested--^a^Hosmer-Lemeshow Goodness-of-fit test: Chi-square, 1.6; *P*-value, 0.90

Given the co-linearity observed between renal dysfunction elevated troponin values, a sub-group analysis of patients without acute renal failure was performed. The results of the bivariate and multivariable models were similar in nature to the original analysis, as troponin values remained significantly associated with in-hospital mortality (adjOR 3.3; 95%CI, 1.2--9.0).

Discussion {#Sec7}
==========

Our study found that patients with elevated troponin values and MRSA IE were associated with increased in hospital mortality. The overall observed inpatient mortality rate was 12%, which is lower than published literature \[[@CR3]\]; one explanation is the large number of patients with mainly associated right-sided IE (65%).

In our study, which is to our knowledge the largest to-date evaluating the role of troponin as a predictor of mortality, patients presenting with an elevated troponin had an adjusted OR of 2.5 of death before discharge (95% CI 1.1--5.6), confirming previous published reports describing an inverse relationship between survival and increased troponin levels, and indicating the importance of obtaining troponin levels for admitted patients with IE to help stratify their mortality risk \[[@CR9], [@CR10]\].

Few previous reports with small sample sizes described elevated troponin as surrogate for increased likelihood of death in patients with IE. Purcell et al. reported increased troponin levels in 65% of 51 patients with IE studied, the study also described an association with central nervous system involvement and death \[[@CR12]\]. Tsenovoy et al. reported increased troponin I levels in 57% of 62 patients with IE, with in-hospital mortality or valve replacement occurring in 18 patients (51%) of the increased troponin arm; these findings were also demonstrated by Stancoven and colleagues \[[@CR13], [@CR14]\]. Gucuk et al. found that troponin levels could also predict one-year survival rates in IE, with 41% mortality rate during follow up in patients with higher troponin levels during initial hospitalization \[[@CR9]\]. There has been postulation that an elevated troponin level indicates myocardial involvement of infection. This would likely indicate a more significant infection compared to only endocardium or valvular involvement. Another possibility is that elevated troponins are associated with more severe sepsis, such as that associated with demand ischemia \[[@CR9], [@CR12]\].

Other predictors of inpatient mortality described in our report included patients older than 40 years of age, severe sepsis or shock on presentation; these predictors are similar to previously described literature emphasizing the importance of initial presentation with multi-organ dysfunction and risk of systemic embolization \[[@CR15]--[@CR19]\]. In a study by Ferrera et al., IE patients presenting with atrial fibrillation had higher in-hospital mortality independently from other relevant clinical variables \[[@CR21]\]. Our findings are similar, but ultimately atrial fibrillation was not associated with in-hospital mortality in the final parsimonious model.

We did find an association between different organisms including MRSA and mortality, some reports suggested increased mortality with *S. aureus* \[[@CR22], [@CR23]\], and other reports did not \[[@CR24]\]. The PWID population remains of high-interest due to increasing incidence of IE and significant morbidity and long-term complication \[[@CR5]\].

The limitations of our study included that it is a single center study with high percentage of PWID, and the results may not be reflective of the general population. However, given the lasting negative effects of the opioid epidemic in the United States, we feel these data likely represent a common patient population particularly throughout the southern United States \[[@CR25], [@CR26]\]. Another limitation was in the retrospective data collection through the electronic medical record, limiting the ability to gather additional information on each patient especially pertaining to drug use and/or other variables that may be associated with in-patient mortality. However, we attempted to correct for confounding variables through multivariable logistic regression methods. We did not collect information on treatment regimens and need for surgery during hospitalization, and patients leaving against medical advice and loss to follow up data.

Conclusion {#Sec8}
==========

The incidence of inpatient mortality was higher in patients with IE and elevated cardiac troponin I levels compared to patients with normal levels; cardiac troponin I may have potential as a prognostic marker in IE.

HIV/AIDS

:   Human immunodeficiency virus/acquired immune deficiency

IE

:   Infective endocarditis

LAMA

:   Left against medical advice

MRSA

:   Methicillin-resistant *Staphylococcus aureus*

PWID

:   People who inject drugs
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